

Clinical Outcomes of Metformin Use in Populations with Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review.

Crowley MJ, et al. Ann Intern Med. 2017; 166(3): 191-200.

- Based on recent changes to its U.S. FDA boxed warning, metformin can now be prescribed for many individuals for whom it was earlier contraindicated/needed to be used with caution.
- Analyses of pooled data from observational studies in the above populations has highlighted that metformin use is associated with:
 - Reduced all-cause mortality in patients with moderate to severe chronic kidney disease (CKD), congestive heart failure (CHF), or chronic liver disease (CLD) with hepatic impairment.
 - Fewer heart failure readmissions in patients with CKD or CHF.

Metformin use in patients with moderate CKD, CHF, or hepatic impairment is associated with improvements in key clinical outcomes.